Skip to main content

ARN pending: Preview site: the distributor's registration details (ARN, EUIN) are being added. We do not accept investments yet.

sipdhara
sipdhara

Language

Currency₹ INR
Currency

Fund NAVs stay in rupees. Other amounts are converted at daily exchange rates.

Number format

Overview

NAV

₹49.4070

Gain 0.45% 1-day changeData as of 9 Oct 2026

1 year
Gain 14.3%
3 years
Gain 20.7%
5 years
Gain 15.2%
Riskometer: Very High risk
RiskometerVery High

The principal will be at Very High risk

Loading chart…

Data as of 9 Oct 2026Source: amfiHow we calculatePast performance may or may not be sustained in future. Returns shown are not an indication of future returns.

Trailing returns

Periods under 1 year show absolute return. 1 year and longer show CAGR (annualised).

Trailing returns
PeriodThis fundNifty Healthcare TRICategory average
1 monthLoss 3.28%Loss 4.38%Loss 4.44%
3 monthsGain 0.27%Loss 2.62%Loss 2.46%
6 monthsGain 20.68%Gain 12.17%Gain 5.91%
1 yearGain 14.30%Gain 9.18%Gain 0.97%
3 yearsGain 20.71%Gain 19.13%Gain 12.50%
5 yearsGain 15.16%Gain 12.78%Gain 10.56%
7 yearsGain 25.86%Gain 21.06%Gain 16.06%
10 years—Gain 10.42%Gain 12.77%
Since launchGain 22.47%Gain 14.63%Gain 9.97%

SIP returns (XIRR)

XIRR of a monthly SIP over each period, valued at the latest NAV.

SIP returns (XIRR)
PeriodThis fundNifty Healthcare TRICategory average
1 yearGain 19.58%Gain 9.38%Gain 0.98%
3 yearsGain 13.90%Gain 11.51%Gain 5.05%
5 yearsGain 18.41%Gain 16.07%Gain 10.31%
10 years—Gain 15.23%Gain 13.57%

Calendar-year returns

This fund 2021: ▲ +25.1%+25Nifty Healthcare TRI 2021: ▲ +19.1%2021This fund 2022: ▼ −6.5%−6Nifty Healthcare TRI 2022: ▼ −10.1%2022This fund 2023: ▲ +36.8%+37Nifty Healthcare TRI 2023: ▲ +34.0%2023This fund 2024: ▲ +42.6%+43Nifty Healthcare TRI 2024: ▲ +41.4%2024This fund 2025: ▼ −4.6%−5Nifty Healthcare TRI 2025: ▼ −1.5%2025This fund 2026 (year to date): ▲ +13.5%+13Nifty Healthcare TRI 2026 (year to date): ▲ +8.8%2026*
This fundNifty Healthcare TRI* 2026 (year to date)
Show as table
Calendar-year returns
YearThis fundNifty Healthcare TRI
2026 (year to date)▲ +13.49%▲ +8.83%
2025▼ −4.55%▼ −1.50%
2024▲ +42.61%▲ +41.36%
2023▲ +36.80%▲ +33.99%
2022▼ −6.50%▼ −10.11%
2021▲ +25.11%▲ +19.08%
2020▲ +79.99%▲ +57.89%
2019▲ +9.58%▼ −5.92%

Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.

Rolling returns

Returns over every possible holding period since launch show the range of outcomes an investor could have had, not just one start date.

Rolling returns
Holding period1Y3Y5Y
Lowest−14.02%14.73%14.25%
Median21.21%22.79%25.27%
Average26.88%23.61%23.98%
Highest97.11%35.15%35.56%
Periods with a loss18.7%0.0%0.0%
Periods above 8%72.5%100.0%100.0%
Periods above 10%69.8%100.0%100.0%
Periods above 12%66.0%100.0%100.0%
Number of periods16701197705

Distribution and comparison with the benchmark

Past performance may or may not be sustained in future. Returns shown are not an indication of future returns.

Risk measures (3 years)

Calculated on daily NAVs over the last 3 years. Tap ? for a plain-language explanation.

Standard deviation
12.91%
Sharpe ratio
1.13
Sortino ratio
1.58
Beta
0.69
Alpha
▲ +5.25%
Maximum drawdown
▼ −16.09%
Up-market capture
88.2%
Down-market capture
71.0%

Beta, alpha and capture ratios are measured against Nifty Healthcare TRI.

Fund facts

Fund size (AUM)
₹3,648 Cr
Expense ratio (TER)
0.75%
Exit load
Not available
Minimum SIP
₹100
Minimum lumpsum
₹500
Launch date
12 Nov 2018
Fund managers
Chirag Dagli
Benchmark index
Nifty Healthcare TRI
Category
Equity: Sectoral / Thematic
Fund house
DSP Mutual Fund
Scheme type
Open Ended
AMFI scheme code
145454
ISIN
INF740KA1LG1

Investment objective

The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities.

Portfolio holdings

Portfolio holdings
HoldingWeight
IPCA Laboratories LimitedPharmaceuticals & Biotechnology8.13%
Sun Pharmaceutical Industries LimitedPharmaceuticals & Biotechnology7.44%
Cipla LimitedPharmaceuticals & Biotechnology7.18%
TREPS / Reverse Repo Investments6.81%
Sai Life Sciences LimitedPharmaceuticals & Biotechnology6.52%
Gland Pharma LimitedPharmaceuticals & Biotechnology6.15%
Apollo Hospitals Enterprise LimitedHealthcare Services6.07%
Globus Medical Inc5.15%
Alkem Laboratories LimitedPharmaceuticals & Biotechnology4.75%
Divi's Laboratories LimitedPharmaceuticals & Biotechnology4.17%
Cohance Lifesciences LimitedPharmaceuticals & Biotechnology3.79%
Alembic Pharmaceuticals LimitedPharmaceuticals & Biotechnology3.18%
Kovai Medical Center And Hospital LimitedHealthcare Services2.83%
Pfizer LimitedPharmaceuticals & Biotechnology2.72%
Concord Biotech LimitedPharmaceuticals & Biotechnology2.70%

Portfolio as of 30 Sept 2026 · top 15 of 34 holdings, 77.6% of the portfolio

Try this fund in our tools

See how a SIP, a lumpsum or withdrawals in this fund would have done, using its real NAV history.

Data sources

Data sources
DataSourceAs of
Latest NAVamfi9 Oct 2026
NAV historycaptnemo9 Oct 2026
Expense ratioamfi9 Oct 2026
Fund sizeamfi8 Oct 2026
Fund managerskuvera11 Oct 2026
Riskometeramfi8 Oct 2026
Scheme detailsamfi9 Oct 2026
Holdingsamc:dsp30 Sept 2026
Benchmarkniftyindices9 Oct 2026
minSipkuvera11 Oct 2026
minLumpsumamfi9 Oct 2026
objectivekuvera11 Oct 2026
launchamfi9 Oct 2026

How we calculate

Mutual fund investments are subject to market risks, read all scheme related documents carefully.